SynCav-1

CINCINNATI--(BUSINESS WIRE)-- Eikonoklastes Therapeutics, a biopharmaceutical company developing a novel gene therapy platform to discover and develop critical treatments for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the formation of a Scientific Advisory Board (SAB) - Gene Therapy, comprised of key leaders in neurology and gene therapy development. The SAB – Gene Therapy will work cohesively with management to advance the company’s gene therapy pipeline. Eikonoklastes’s gene therapy platform is built upon the pioneering work from the lab of Dr. Brian Head, Professor of Anesthesiology at University of California, San Diego. “I am very pleased to join Eikonoklastes’ Scientific Advisory Board,” said Dame Pamela Shaw, DBE, MD. “I look forward to working with this distinguished group of industry experts to advise the Eikonoklastes team through the development of its innovative technology to address enormous unmet clinical needs.” “We are fortunate to have the support of a truly world-class group of scientific and industry thought leaders on our Scientific Advisory Board, who will offer their expertise to ensure we optimally design our development program to meet the needs of patients and rapidly advance this technology through regulatory approval to treat patients with this devastating disease,” said Bruce Halpryn, Ph.D., Board Chair and CEO of Eikonoklastes. “Each member brings unique experience in technology, manufacturing, regulatory affairs, and clinical development. This collection of unparalleled expertise will serve us well as we develop our lead candidate, ET-101, initially for ALS and expanding into several other inadequately treated neurodegenerative diseases,” said Samuel Lee, MD, MBA, MPH, President and Chief Business Officer of Eikonoklastes. The founding members of the Eikonoklastes Scientific Advisory Board – Gene Therapy are: Brian Head, PhD Research Career Scientist, VA San Diego Healthcare System Professor of Anesthesiology, University of California – San Diego Russell Lonser, MD Chairman, Department of Neurological Surgery, Ohio State University Wexner Medical Center Director, Gene Therapy Institute, Ohio State University Professor of Neuroscience, Ohio State University College of Medicine Michael O’Beirne Former Executive Director, Regulatory Strategy at Sarepta Therapeutics Vaithianathan “Palani” Palaniappan, PhD Chief Technology Officer, Pioneering Medicines at Flagship Pioneering Former Head of Global Technical Operations, Sarepta Former Global Head of Biologics and New Modality Development, Takeda Seward Rutkove, MD Chair, Department of Neurology at Beth Israel Deaconess Medical Center Professor of Neurology, Harvard Medical School Dame Pamela Shaw, DBE, MD Founder and Director, Sheffield Institute for Translational Neuroscience Professor of Neurology, University of Sheffield Mark Tuszynski, MD, PhD Director, UC San Diego Translational Neuroscience Institute Distinguished Professor of Neuroscience, University of California – San Diego About Eikonoklastes Therapeutics Eikonoklastes Therapeutics is a biotech company rapidly developing a pipeline of disruptive new treatments for today’s most challenging diseases. The company’s 1st-in-class gene therapy (ET-101) has been engineered to overexpress Caveolin-1, which organizes and regulates synaptic receptors essential for neuromuscular signaling and function. Eikonoklastes is also advancing a new generation of tissue factor (TF) therapies (ET-201) for the treatment of Triple Negative Breast Cancer and other oncology indications. To learn more, visit